CoreWeave Stock Wipeout Exposes Divide Between AI Fear and Greed

CoreWeave Inc. has become ground zero in a tug of war between investors who see rising bond yields as a potential rally killer for the AI trade and those who think demand for computing power will make those concerns seem passé before long.

The cloud-computing services provider's shares plunged 20% in the first three sessions of the week, including more than 15% on Wednesday, as its debt tumbled to levels that typically indicate distress. On Thursday morning, the cost of protecting CoreWeave bonds against default rose to the highest intraday level on record, while swaps priced in a more than 60% chance of default within the next five years.

But by Thursday afternoon, the sense of panic appeared to be easing as the stock bounced into the green after Jensen Huang, chief executive of Nvidia Corp., a CoreWeave shareholder and supplier, expressed confidence in the company. In addition, Deutsche Bank called the selloff a "buying opportunity." The shares ended the day up 5.9%, their best performance in over a month, though they gave up some of that recovery in Friday's premarket trading.

"The macro backdrop has created a sell-first, ask-questions-later market," said Thomas DiFazio, exchange-traded fund strategist at Roundhill Financial. "In the short run, it is hard to say with a straight face that the all-clear is here."

As a so-called neocloud provider, CoreWeave is at the heart of the infrastructure buildout needed to develop artificial intelligence technology. The safety of its debt is a key issue for investors because its spending on building data centers is being funded by issuing bonds. Yahoo Finance reports.

🧬 Nvidia-Backed AI Biotech Iambic Up 16% After $150 Million IPO

Iambic Therapeutics Inc. (IAM) shares soared 16% in its trading debut after the clinical-stage cancer drugmaker and technology firm raised $150 million in a U.S. initial public offering.

The biotech's shares traded at $18.50 each as of 12:21 p.m. in New York on Thursday, after trading was paused for volatility, above its IPO price of $16 per share.

At that price, the firm, which counts Nvidia Corp. (NVDA) as a shareholder, had a market value of $877 million, based on its outstanding shares.

The San Diego-based firm uses AI and machine learning to help discover new treatments, according to the filing. Iambic will use the proceeds from the IPO to advance three early-stage cancer drug candidates.

ARK Investment Management, which is already an investor in Iambic, and billionaire Stanley Druckenmiller's Duquesne Family Office had expressed interest in buying up to $60 million worth of shares in the offering in aggregate.

The oncology-focused firm is poised to capitalize on investor excitement about the potential for artificial intelligence to speed up biological discoveries. Yahoo Finance reports.

🏢 SITE Centers (SITC) Stock Jumps 19% After Hours: What’s Driving the Surge?

SITE Centers Corp. (NYSE: SITC) shares climbed 18.94% to $3.58 in Friday's premarket session after the real estate investment trust announced a $3-per-share special cash distribution and a plan to voluntarily delist from the New York Stock Exchange.

In a Thursday filing with the Securities and Exchange Commission, SITE Centers said its board declared the special distribution, payable Nov. 5 to shareholders of record on Oct. 27. The company also agreed to sell its interests in the Dividend Trust Portfolio joint venture for net proceeds of about $32.4 million. Benzinga reports.

✈️ Why Is NextTrip (NTRP) Stock Falling After Hours?

NextTrip Inc. (NASDAQ: NTRP) shares fell 13.17% to $1.45 in after-hours trading on Thursday.

NextTrip is a technology-forward travel and media company that operates the JOURNY TV channel and the NextTrip Pro platform for travel agencies and advisors.

According to a press release published Thursday, the company reported preliminary results for its fiscal second quarter and the six months ended Aug. 31, 2026. Benzinga reports.

🧪 Recursion Pharmaceuticals (RXRX) Stock Is Trending After Hours

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) shares are trending on Friday.

Shares of the Utah-based clinical-stage biotechnology company edged 0.24% higher to $4.17 after the bell on Thursday, following a $200 million stock offering.

Recursion priced an underwritten offering of 61.54 million Class A shares at $3.25 each Gross proceeds are expected to be approximately $200 million before fees. The offering is expected to close on or about Friday. Benzinga reports.

💊 Big Pharma Stocks Close Near All-Time Highs as Tech Selloff Pushes Investors Toward Safer Bets

Biopharma stocks like AbbVie and Eli Lilly closed near their all-time highs in the latest signal that investors are seeking out the steady gains that come with large, diversified drugmakers.

These companies are doing what they do best: investing in the pipelines of the future and extending the patent lives of their top-selling drugs. Against the turbulence in tech stocks in recent months, that kind of solid, known performance appeals to investors.

The State Street Health Care Select Sector SPDR Exchange-Traded Fund (XLV), which is heavily weighted by Lilly and AbbVie, reached an all-time high of $177.19 on Thursday, gaining 5.6% over the past five days. On Thursday, investors also turned to consumer staples and government bonds amid a selloff in AI-related stocks over concerns about AI expenditures and Anthropic’s cooling revenue growth. MarketWatch reports.

(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM ET). Stock Analysis reports.

1) JAGX: Jaguar Health, Inc.
Total gain: +45.53%

2) TCRT: Alaunos Therapeutics, Inc.
Total gain: +33.03%

3) PMI: Picard Medical, Inc.
Total gain: +23.50%

4) SITC: SITE Centers Corp.
Total gain: +18.27%

5) EVAX: Evaxion A/S
Total gain: +13.57%

The closing price of the top three market percent gainers trading near or above $2 on Oct 15.

(All pricing and percent gains are based on regular market trading hours from 9:30 AM to 4:00 PM ET). Stock Analysis reports.

1) BETR: Better Home & Finance Holding Company
Total gain: +32.51%

The company announces that a class action lawsuit has been filed against Better Home & Finance Holding Company ("Better Home & Finance" or the "Company") (NASDAQ: BETR) on behalf of investors that purchased or otherwise acquired Better Home & Finance securities between March 13, 2026 and May 7, 2026 (the "Class Period"). Newsfilecorp reports.

2) INDP: Indaptus Therapeutics, Inc.
Total gain: +28.96%

The stock appeared to be moving on no notable news.

3) PTLE: PTL Limited
Total gain: +23.13%

The stock appeared to be moving on no notable news.

(Estimate and Actual numbers represent Earnings Per Share in US Dollars)

MTB

M&T Bank

Q3 2026

Before Market Open

Estimate: 4.940

Actual: 5.080

TRV

Travelers Companies

Q3 2026

Before Market Open

Estimate: 7.350

Actual: N/A

CFG

Citizens Financial Group

Q3 2026

Before Market Open

Estimate: 1.380

Actual: N/A

Time (ET) / Report / Period

• 8:30 AM / Import Prices / Sep
• 9:15 AM / Industrial Production, M/M% / Sep
• 9:15 AM / Capacity Utilization % / Sep

“When investing, pessimism is your friend, euphoria the enemy.”

– Warren Buffett

Sourced in: Berkshire Hathaway, 2008 Shareholder Letter, page 5

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference.

The information in this newsletter summarizes the latest market activity and related news and are provided for educational purposes only. Any trading symbols displayed are for illustrative purposes only and do not constitute a recommendation by TradeZero to buy, sell, or hold any investment. This material is not intended to provide investment advice or to take into account any individual’s financial condition, investment objectives, or requirements.

Investing involves risk, including the possible loss of principal.

There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses.

Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

Stocks experiencing significant price volatility may involve substantial risk. Past performance is no guarantee of future results.

Any trading strategies discussed are for educational purposes only and should not be construed as investment advice or a recommendation.

Certain information herein has been obtained from third-party sources believed to be reliable; however, its accuracy or completeness cannot be guaranteed. The views and opinions expressed are those of the author and do not necessarily reflect the views or opinions of TradeZero, its affiliates, or employees.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.

Copyright © TradeZero 2026. All rights reserved.